Free Trial

Coherus BioSciences (CHRS) Competitors

$2.08
0.00 (0.00%)
(As of 05/21/2024 ET)

CHRS vs. MGX, GLUE, AGEN, ZURA, CMPX, ABOS, IPHA, STRO, OPT, and INMB

Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Metagenomi (MGX), Monte Rosa Therapeutics (GLUE), Agenus (AGEN), Zura Bio (ZURA), Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), Sutro Biopharma (STRO), Opthea (OPT), and INmune Bio (INMB). These companies are all part of the "biological products, except diagnostic" industry.

Coherus BioSciences vs.

Coherus BioSciences (NASDAQ:CHRS) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.

Coherus BioSciences received 427 more outperform votes than Metagenomi when rated by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 65.07% of users gave Coherus BioSciences an outperform vote.

CompanyUnderperformOutperform
Coherus BioSciencesOutperform Votes
436
65.07%
Underperform Votes
234
34.93%
MetagenomiOutperform Votes
9
90.00%
Underperform Votes
1
10.00%

Metagenomi has a net margin of 0.00% compared to Coherus BioSciences' net margin of -19.64%.

Company Net Margins Return on Equity Return on Assets
Coherus BioSciences-19.64% N/A -33.10%
Metagenomi N/A N/A N/A

Metagenomi has lower revenue, but higher earnings than Coherus BioSciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$257.24M0.93-$237.89M-$0.78-2.67
Metagenomi$44.76M5.94-$68.25MN/AN/A

In the previous week, Metagenomi had 10 more articles in the media than Coherus BioSciences. MarketBeat recorded 13 mentions for Metagenomi and 3 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.17 beat Metagenomi's score of -0.33 indicating that Coherus BioSciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coherus BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Metagenomi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

72.8% of Coherus BioSciences shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Coherus BioSciences presently has a consensus target price of $8.83, indicating a potential upside of 324.68%. Metagenomi has a consensus target price of $17.83, indicating a potential upside of 151.17%. Given Coherus BioSciences' higher probable upside, research analysts plainly believe Coherus BioSciences is more favorable than Metagenomi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus BioSciences
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Metagenomi
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

Metagenomi beats Coherus BioSciences on 8 of the 14 factors compared between the two stocks.

Get Coherus BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHRS vs. The Competition

MetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$238.64M$3.00B$5.02B$8.00B
Dividend YieldN/A2.18%42.66%3.91%
P/E Ratio-2.6730.71181.6318.70
Price / Sales0.93372.282,520.3684.54
Price / CashN/A170.4332.8429.27
Price / Book-1.204.325.014.46
Net Income-$237.89M-$45.93M$104.15M$213.44M
7 Day Performance-4.59%-1.53%0.27%0.46%
1 Month Performance-4.59%9.27%4.09%5.46%
1 Year Performance-53.36%1.80%4.84%8.75%

Coherus BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGX
Metagenomi
0 of 5 stars
$6.54
-0.2%
$17.83
+172.7%
N/A$245.05M$44.76M0.00236Positive News
GLUE
Monte Rosa Therapeutics
0.7379 of 5 stars
$5.00
+1.0%
$11.00
+120.0%
-24.3%$252.55MN/A-1.98133Gap Up
AGEN
Agenus
3.6895 of 5 stars
$10.70
-3.5%
$70.00
+554.2%
-60.3%$224.70M$156.31M-0.83389
ZURA
Zura Bio
3.6355 of 5 stars
$5.16
+7.7%
$18.83
+265.0%
+6.4%$222.37MN/A0.0014
CMPX
Compass Therapeutics
2.2583 of 5 stars
$1.62
+3.2%
$9.00
+457.3%
-49.5%$222.21MN/A-4.7532Gap Down
ABOS
Acumen Pharmaceuticals
3.1949 of 5 stars
$3.69
+9.8%
$12.25
+232.0%
-36.1%$221.70MN/A-3.3939Earnings Report
Gap Up
IPHA
Innate Pharma
2.1516 of 5 stars
$2.64
+1.1%
$9.75
+269.3%
-0.7%$213.47M$66.71M0.00179
STRO
Sutro Biopharma
4.7391 of 5 stars
$4.34
+2.6%
$12.50
+188.0%
-16.1%$264.13M$153.73M-2.44302Gap Up
OPT
Opthea
0.9952 of 5 stars
$3.61
-1.6%
$14.00
+287.8%
-8.0%$210.82M$110,000.000.0024
INMB
INmune Bio
0.7066 of 5 stars
$10.49
+5.7%
$16.00
+52.5%
+43.5%$207.49M$160,000.00-5.4611

Related Companies and Tools

This page (NASDAQ:CHRS) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners